Pharmacogenomics: will the promise be fulfilled?

被引：22
|
作者：
Altman, Russ B. [1 ]
Kroemer, Heyo K. [2 ]
McCarty, Catherine A. [3 ]
Ratain, Mark J. [4 ]
Roden, Dan [5 ]
机构：
[1] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA
[2] Ernst Moritz Arndt Univ Greifswald, Res Ctr Pharmacol & Expt Therapeut, D-17487 Greifswald, Germany
[3] Marshfield Clin Res, Ctr Human Genet, Marshfield, WI 54449 USA
[4] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[5] Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA
来源：
NATURE REVIEWS GENETICS | 2011年 / 12卷 / 01期
关键词：
MAJOR DETERMINANT; GENOME-WIDE; CLOPIDOGREL; ASSOCIATION; GENOTYPE;
D O I：
10.1038/nrg2920
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Tools such as genome resequencing and genome-wide association studies have recently been used to uncover a number of variants that affect drug toxicity and efficacy, as well as potential drug targets. But how much closer are we to incorporating pharmacogenomics into routine clinical practice? Five experts discuss how far we have come, and highlight the technological, informatics, educational and practical obstacles that stand in the way of realizing genome-driven medicine.
引用
收藏
页码：69 / 73
页数：5
相关论文
共 50 条
12345